Holen Sie sich die Stockscreener-App
7.915
8.57%
0.625
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Recovery Setup Building in Mersana Therapeutics Inc. Experts Say2025 Valuation Update & Technical Buy Zone Confirmation - thegnnews.com
Sector Leaders Rotate Capital Into Mersana Therapeutics Inc.Trade Risk Assessment & Risk Controlled Stock Pick Alerts - classian.co.kr
How to forecast Mersana Therapeutics Inc. trends using time series2025 Year in Review & Reliable Volume Spike Trade Alerts - Newser
Using portfolio simulators with Mersana Therapeutics Inc. includedMarket Sentiment Summary & Risk Controlled Stock Pick Alerts - Newser
How Mersana Therapeutics Inc. stock performs during market volatilityMarket Growth Report & Reliable Entry Point Trade Alerts - Newser
Leerink Partnrs Has Pessimistic View of MRSN Q3 Earnings - Defense World
Will Mersana Therapeutics Inc. outperform the market2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser
Will Mersana Therapeutics Inc. benefit from macro trends2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Best data tools to analyze Mersana Therapeutics Inc. stock2025 Trading Volume Trends & Growth-Oriented Investment Plans - Newser
Mersana Therapeutics Inc.’s volatility index tracking explained2025 Big Picture & Capital Efficiency Focused Ideas - Newser
Combining machine learning predictions for Mersana Therapeutics Inc.July 2025 Intraday Action & Growth Focused Entry Point Reports - Newser
Full technical analysis of Mersana Therapeutics Inc. stock - Newser
Combining price and volume data for Mersana Therapeutics Inc.Portfolio Return Report & Precise Trade Entry Recommendations - Newser
Volatility clustering patterns for Mersana Therapeutics Inc.July 2025 Short Interest & Smart Money Movement Alerts - Newser
Guggenheim Cuts Mersana Therapeutics (NASDAQ:MRSN) Price Target to $30.00 - Defense World
Top chart patterns to watch in Mersana Therapeutics Inc.Long Setup & Stepwise Entry and Exit Trade Signals - Newser
Truist Financial Cuts Mersana Therapeutics (NASDAQ:MRSN) Price Target to $36.00 - Defense World
Mersana Therapeutics Inc. stock volume spike explainedPortfolio Risk Summary & Comprehensive Market Scan Reports - Newser
What’s the recovery path for long term holders of Mersana Therapeutics Inc.2025 Price Action Summary & Low Risk Entry Point Tips - Newser
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 PreEarnings & Fast Entry High Yield Tips - Newser
Can Mersana Therapeutics Inc. recover in the next quarter2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsPrice Action & Risk Managed Investment Signals - Newser
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone - MSN
Will earnings trigger a reversal in Mersana Therapeutics Inc.Weekly Risk Summary & Weekly Setup with High ROI Potential - Newser
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
How to escape a deep drawdown in Mersana Therapeutics Inc.July 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
Automated trading signals detected on Mersana Therapeutics Inc.July 2025 Action & Risk Managed Trade Strategies - Newser
Competitive Positioning of Mersana Therapeutics Inc.: Is It Leading or LaggingQuarterly Investment Review & Weekly Hot Stock Watchlists - Newser
Mersana Misses Fiscal Q2 Revenue Target - AOL.com
Chart overlay techniques for tracking Mersana Therapeutics Inc.Trend Reversal & Daily Momentum Trading Reports - Newser
Mersana Therapeutics Inc. Nearing Breakout Level After BounceJuly 2025 PreEarnings & Real-Time Stock Movement Alerts - beatles.ru
Will Mersana Therapeutics Inc. stock go up soonMarket Growth Review & Verified Technical Trade Signals - Newser
Rainbows and Unicorns: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Just Became A Lot More Optimistic - simplywall.st
Mersana Therapeutics Positioned Favorably with Promising Developments and Strategic Adjustments Supporting Buy Rating - TipRanks
Mersana Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN
Mersana Therapeutics price target adjusted to $36 at Truist after reverse split - MSN
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates - MSN
Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25) - MSN
Truist Securities slashes Mersana stock price target to $36 from $250 - Investing.com Canada
Mersana Therapeutics Q2 2025 Earnings Preview - MSN
Guggenheim Downgrades Mersana Therapeutics to Buy, PT to $30 from $125. - AInvest
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript - Insider Monkey
Guggenheim lowers Mersana stock price target to $30 from $125 By Investing.com - Investing.com Canada
Mersana Therapeutics 2025 Q2 Earnings Slight EPS Improvement Amid Widening Net Loss - AInvest
Mersana Therapeutics Faces Financial Strain Amid U.S. Tariff Uncertainties - TipRanks
Mersana Therapeutics Inc. Bounces Off Moving Average SupportJuly 2025 Update & Expert Curated Trade Setups - beatles.ru
Mersana Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Mersana stock price target raised to $17 from $6 at BTIG - Investing.com Canada
Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics - TipRanks
Mersana Therapeutics (MRSN): Assessing the Path to Value Recovery Amid Clinical Progress and Financial Challenges - AInvest
Mersana Therapeutics Q2 2025: Unpacking Key Contradictions in Clinical Strategies and Patient Eligibility - AInvest
Mersana Therapeutics: Emi-Le Expansion Data Expected in H2 2025, $15M GSK Milestone Achieved - AInvest
Mersana Therapeutics shares rise 1.90% intraday after reporting 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts. - AInvest
Transcript : Mersana Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Mersana Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
1.13%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):